ArchiveNovember 2017

Copaxone: yet another mechanism

Previously on this blog I’ve written about Copaxone and its “mechanism of the week”. For example, here and here. I haven’t done it for a while, but can’t resist bringing this one to your attention. Now it’s anti-bacterial. What next? It inhibits EBV 🙂 But I guess it must be working by blocking the microbiome:-). Christiansen SH, Murphy RA, Juul-Madsen K...

Can coffee really be good for you?

As you see we are trying to post less often on the blog so that you have more time to read and discuss the posts. The following blog post is a bit of a cheat as I have reviewed three papers. However, they are all related to coffee and are relevant to pwMS and their families. Are you addicted to coffee? If you are, don’t worry, the latest research suggests it may be good for you...

Alemtuzumab hair today gone tommorrow

NeuroDoc Gnanapavan I didn’t sign-up for this!  I want my hair back ;-( Front Neurol. 2017 Oct 30;8:569. doi: 10.3389/fneur.2017.00569. eCollection 2017. Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity-Report of a Case and Review of the Literature. Zimmermann J, Buhl T, Müller M. Secondary...

Training the next generation of UK’s MSologists

Tony Blair is famously quoted as saying ‘Education, education, education, …’ and putting education at the centre of New Labour’s manifesto in 1997. However, is it the type or the quality of education that makes the difference and changes the world? We are trying to change the world of MS treatment. I have learned that information in itself may pique attention, but it...

Study shows a B cell depleting treatment is effective

A new study tests a B cell depleting treatment in MS. The results are interesting. Anti-CD19 depletion kills off most B cell types, except the plasma cell (antibody secreting cell). So when an anti-CD20, anti B cell treatment (i.e. ocrelizumab) inhibits MS, the T cellers say it is killing the 5-20% of CD20 positive T cells which contain the pathogenic cell population. This flimsy...

Are we Overdosing Ocrelizumab

The eagles (ocrelizumab for RRMS and PPMS)  may have landed in Europe, but how often should the birds be used to kill cells in MS? A view-point argues it’s too often and that it can be personalised and smart.  I agree but for different reasons….. Avasarala J. Anti-CD20 Cell Therapies in Multiple Sclerosis-A Fixed Dosing Schedule for Ocrelizumab is Overkill. Drug Target...

Searching for the Miracle Cure. MS in the Media

Last night we had a programme in the UK on  someones journey to Israel to examine the effect of mesenchymal stem cells. Mesenchyme is embryonic connective tissue that is derived from the mesoderm and that differentiates into haematopoietic and connective tissue, whereas MSCs do not differentiate into haematopoietic cells. It was dubbed a...

Guest post: Young carers in Newcastle try Digesting Science

We have recently reached out to a number of young carer organisations across the country, encouraging them to hold a Digesting Science event (the Barts-MS set of activities explaining MS to 6-12 year olds). Recently, we got some great feedback from the South Tyneside Young Carers, and thought we’d share their fantastic work with you. Post by Levi Cosker, South Tyneside Young Carers Activity...

Who Needs T cells..Not EBV infected Memory B cells

To finish off the debate…a prominent T cell immunologist in the red corner said B cells need T cells…..However, do some reading and listening and as said with EBV in the equation…maybe not. Did people listen to the Evidence with an open mind and no preconceptions? Epstein–Barr virus latent membrane protein 1 (LMP1) is an Epstein–Barr virus (EBV) protein.  Rastelli J, Hömig...

Translate

Categories

Recent Posts

Recent Comments

Archives